Last reviewed · How we verify
rHDL
At a glance
| Generic name | rHDL |
|---|---|
| Sponsor | CSL Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Trial to Evaluate the Ability of a Single Infusion of High-Density Lipoprotein (HDL) to Modulate Markers of Cerebral Ischaemia (NA)
- Improving Metabolism With HDL Cholesterol (NA)
- Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rHDL CI brief — competitive landscape report
- rHDL updates RSS · CI watch RSS
- CSL Limited portfolio CI